Results 141 to 150 of about 176,716 (160)

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

Annals of Oncology, 2004
Virginia Filiaci, Holly H Gallion, T Herzog   +2 more
exaly  

Doxorubicin see Cisplatin/doxorubicin

Reactions, 1988
openaire   +1 more source

Doxorubicin, DNA torsion, and chromatin dynamics

Biochimica Et Biophysica Acta: Reviews on Cancer, 2014
Sheila Teves, Steven Henikoff, Christopher J Kemp   +2 more
exaly  

Doxorubicin

Reactions Weekly, 2009
openaire   +1 more source

Doxorubicin

Reactions Weekly, 2016
openaire   +2 more sources

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

Journal of Pharmacy and Pharmacology, 2012
Crispin Dass, Pornsak Sriamornsak, Sriamornsak Pornsak   +2 more
exaly  

Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin–PEG–folate conjugate

Journal of Controlled Release, 2004
exaly  

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

European Journal of Cancer, 2001
Jean-Yves Blay, John Radford, C Kamby
exaly  

Doxorubicin

Reactions Weekly, 2013
openaire   +1 more source

Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats

Toxicology, 2005
Yusuf Kalender, Suna Kalender
exaly